The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isApproved for type 2 diabetes with major outcome trials behind it.
- What to watchNausea, vomiting, belly pain and fast breathing even with normal glucose.
How Canagliflozin works
Canagliflozin blocks a transporter, and the transporter is in the kidney rather than anywhere metabolically interesting. Everything else this drug does is downstream of throwing sugar away.
The number that matters for a non-diabetic reader, and it is never stated. Filtered glucose load is glomerular filtration rate multiplied by plasma glucose. In someone with a normal fasting glucose the filtered load is roughly half that, and the fraction the drug can capture is smaller still.
Beyond glucose, the class produces genuine cardiovascular and renal outcome benefits that appear largely independent of the glucose lowering.
- Oral
Can you get Canagliflozin?
An SGLT2 inhibitor for type-2 diabetes. Needs a prescriber managing the diabetes, and none of my partners dispense it.
Research on Canagliflozin7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Strong human outcome trials; rodent lifespan data (males).
Human clinical evidence
Approved for type 2 diabetes with major outcome trials behind it. CANVAS showed reduced major adverse cardiovascular events, and CREDENCE showed a significant reduction in kidney disease progression — a hard renal endpoint that changed practice.
CANVAS also found roughly a doubling of amputation risk, which led to a boxed warning that was later removed after further data. The signal was real in that trial and did not replicate; both facts belong in the record.
It also extended lifespan in male mice in the NIA Interventions Testing Program — again male-only, like acarbose and 17-alpha-estradiol.
Correlative data
Wide prescribing. The consistently reported issues are genital mycotic infections — a direct consequence of putting sugar in the urine — and volume depletion. Euglycemic diabetic ketoacidosis is rare, serious, and easy to miss because blood glucose looks normal.
How the mechanism reads
Inhibits SGLT2 in the proximal tubule, blocking glucose reabsorption so roughly 80 grams a day is excreted in urine. That is a genuinely novel mechanism — it lowers glucose independently of insulin entirely.
MechanisticThe cardiovascular and renal benefits are larger than glucose-lowering explains, and are thought to come from reduced intraglomerular pressure, a shift toward ketone metabolism in the heart, and plasma volume reduction.
MechanisticAnd also behind the caution that it is not a weight drug and carries real infection and DKA risk.
Mechanistic
Sources
- Sharma A, et al. Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial. Journal of the American Heart Association 2024 · PMID 38240199
- Chen AX, et al. An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2024 · PMID 39036974
- Snyder JM, et al. Canagliflozin retards age-related lesions in heart, kidney, liver, and adrenal gland in genetically heterogenous male mice. GeroScience 2023 · PMID 35974129
- Wezeman J, et al. Sex Matters in Aging. The Canagliflozin Story. Aging Pathobiology and Therapeutics 2022 · PMID 36540066
- Lakusic N, et al. Euglycemic diabetic ketoacidosis: A rare but serious side effect of sodium-glucose co-transporter 2 inhibitors. World Journal of Cardiology 2022 · PMID 36339887
- Guo G, et al. Physiologically based pharmacokinetic model of sodium-glucose cotransporter 2 inhibitors predicted pharmacokinetics and pharmacodynamics to explore dosage regimen for patients with type 2 diabetes mellitus and renal insufficiency. Frontiers in Pharmacology 2025 · PMID 40230691
- Klen J, et al. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. International Journal of Molecular Sciences 2021 · PMID 34575958
Canagliflozin safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Type 1 diabetes or any past diabetic ketoacidosis.
- Foot ulcers or peripheral artery disease, because the CANVAS program found more amputations.
- Dehydration, low blood pressure or loop diuretic use.
- Recurrent genital yeast infection or urinary infection.
- Prolonged fasting or a ketogenic diet, which sets the stage for euglycemic ketoacidosis.
What’s expected
- Glucose appears in urine and urination rises.
- Small falls in weight and blood pressure.
- Genital itching or yeast infection from glucose in urine.
Watch for
- Nausea, vomiting, belly pain and fast breathing even with normal glucose.
- A foot sore, toe pain or color change.
- Genital pain, redness and fever, the Fournier's gangrene pattern.
Labs that tell you it’s working
- HbA1c: the glucose effect of blocking renal glucose reabsorption.
- Cystatin C with eGFR: an early dip in filtration is expected, with long-term kidney protection.
- Urinalysis: glucose spill and any urinary infection.
- Comprehensive Metabolic Panel: bicarbonate and sodium for acidosis and volume.
SGLT2 inhibition in the proximal tubule: urinary glucose loss, volume contraction and ketone shift drive its benefits and its hazards. PMID 36339887 PMID 39036974
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Canagliflozin FAQ4 common questions
- Is Canagliflozin approved for human use?
- No. Canagliflozin is a research compound.
- What is Canagliflozin researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- HbA1c; Cystatin C with eGFR; Urinalysis; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Canagliflozin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



